October 25, 2018 09:00 AM EDT

Milestone Pharma grabs an $80M round as it steams into pivotal trial work, starts outlining commercial structure

John Carroll

Editor & Founder

Eleven years after it got started, Milestone Pharmaceuticals has gained the $80 million it needs to explore in a pivotal study whether its new cardio …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Milestone Pharma grabs an $80M round as it steams into pivotal trial work, starts outlining commercial structure

John Carroll

Editor & Founder

Sign up to read this article for free.

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Mile­stone Phar­ma grabs an $80M round as it steams in­to piv­otal tri­al work, starts out­lin­ing com­mer­cial struc­ture

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Milestone Pharma grabs an $80M round as it steams into pivotal trial work, starts outlining commercial structure

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya